SparkMaster 2: New software automates analysis of calcium release events

A team of UC Davis and University of Oxford researchers have developed an innovative tool: SparkMaster 2.

EC approves BeiGene’s tislelizumab for three NSCLC indications – Pharmaceutical Technology

Share this article Tislelizumab is approved under the brand name Tevimbra for the treatment of unresectable or metastatic oesophageal squamous cell carcinoma (ESCC). Credits: Good

April 23, 2024

A U.K. trade group scolds Novo again — this time for remarks made by its CEO

Once again, Novo Nordisk has been admonished by a U.K. trade group for violating voluntary marketing codes and discrediting the entire pharmaceutical industry — and

August 8, 2024

After cutting back on Vuity last fall, AbbVie culls a second-gen presbyopia eye drop

In 2021, AbbVie secured the first FDA approval for an eye drop for presbyopia, but in 2022 the drugmaker reduced sales and marketing on the

June 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.